Black Diamond Therapeutics, Inc
NASDAQ: BDTX10 known investors
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma. The company uses its proprietary MAP drug discovery platform to identify and selectively inhibit mutant driver proteins while sparing wild-type forms.
Founders & leadership
EB
Elizabeth BuckChief Scientific Officer
BH
Brent Hatzis-SchochChief Operating Officer and General Counsel
SY
Sergey YurasovChief Medical Officer
MM
Melanie MorrisonChief Development Officer
Investors · 10
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Nextech InvestZurich · $648K – $3.2M
NSG VenturesSingapore
RA CapitalBoston
Versant VenturesSan Francisco · $250K – $5M
Biotechnology Value FundreportedSan Francisco
Deerfield Management CompanyreportedNew York
Versant Venture CapitalreportedSan Francisco
In the news
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conferencefinance.yahoo.com · Sep 2026Frequently asked questions
- What does Black Diamond Therapeutics, Inc do?
- Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma. The company uses its proprietary MAP drug discovery platform to identify and selectively inhibit mutant driver proteins while sparing wild-type forms.
- Who founded Black Diamond Therapeutics, Inc?
- Black Diamond Therapeutics, Inc was founded by Elizabeth Buck.
- Who are Black Diamond Therapeutics, Inc's investors?
- Black Diamond Therapeutics, Inc's investors include LAV, Lilly Asia Ventures, New Enterprise Associates (NEA), Nextech Invest, NSG Ventures, RA Capital, Versant Ventures, Biotechnology Value Fund and 2 more.
- How much funding has Black Diamond Therapeutics, Inc raised?
- Black Diamond Therapeutics, Inc has disclosed $42.5K raised across 1 round.